Abstract COVID-19-associated coagulopathy (CAC) is a life-threatening complication of
SARS-CoV-2 infection. However, the underlying cellular and molecular mechanisms driving …

The activating interplay of thrombosis and inflammation (thromboinflammation) has been
established as a major underlying pathway, driving not only cardiovascular disease but also …

Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …

Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Thromboembolic events are frequent and life-threating complications of COVID-19 but are
also observed in patients with sepsis. Disseminated thrombosis can occur despite …

Importance Platelet activation is a potential therapeutic target in patients with COVID-19.
Objective To evaluate the effect of P2Y12 inhibition among critically ill patients hospitalized …

Antiplatelet therapy plays a crucial role in a number of cardiovascular disorders. We
currently have a range of antiplatelet agents in our armamentarium. In this review, we aim to …

Background Hemostasis and inflammation are both dysregulated in patients with moderate-
to-severe coronavirus disease 2019 (COVID-19). Yet, both processes can also be disturbed …